Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

The role of gut microbiota tyrosine decarboxylases in levodopa pharmacokinetics: insights from a levodopa challenge test

Feng, Yukun, Zhang, Ronggui, Wen, Guangxin, Xie, Ling, Chen, Tao, Liu, Weiguo·2025·BMC Neurology
DOI 10.1186/s12883-025-04428-6
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12883-025-04428-6

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 21

  1. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of parkinson’s disease. LANCET NEUROL. 2021;20(5):385–97. · DOI · Paper page
  2. Tambasco N, Romoli M, Calabresi P. Levodopa in parkinson’s disease: current status and future developments. CURR NEUROPHARMACOL. 2018;16(8):1239–52. · DOI · Paper page
  3. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: A review. JAMA-J AM MED ASSOC. 2020;323(6):548–60. · DOI · Paper page
  4. Riederer P, Strobel S, Nagatsu T, Watanabe H, Chen X, Loschmann PA, Sian-Hulsmann J, Jost WH, Muller T, Dijkstra JM, et al. Levodopa treatment: impacts and mechanisms throughout parkinson’s disease progression. J NEURAL TRANSM. 2025;132(6):743–79. · DOI
  5. Xu K, Sheng S, Zhang F. Relationship between gut bacteria and Levodopa metabolism. CURR NEUROPHARMACOL. 2023;21(7):1536–47. · DOI
  6. Zhang Y, He X, Mo C, Liu X, Li J, Yan Z, Qian Y, Lai Y, Xu S, Yang X, et al. Association between microbial tyrosine decarboxylase gene and Levodopa responsiveness in patients with Parkinson disease. NEUROLOGY. 2022;99(22):e2443–53. · DOI
  7. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified parkinson’s disease rating scale: comparison with the unified parkinson’s disease rating scale. Mov DISORD. 2013;28(5):668–70. · DOI · Paper page
  8. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of Levodopa dose equivalency reporting in parkinson’s disease. Mov DISORD. 2010;25(15):2649–53. · DOI · Paper page
  9. Saranza G, Lang AE. Levodopa challenge test: indications, protocol, and guide. J NEUROL. 2021;268(9):3135–43. · doi:10.1007/s00415-020-09810-7
  10. Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of Levodopa in the treatment of parkinson’s disease. CURR CLIN PHARMACOL. 2007;2(3):234–43. · DOI
  11. Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to Levodopa during the first 4 years of therapy. ANN NEUROL. 2002;51(6):686–93. · DOI
  12. Brussow H. Parkinson disease, Levodopa and the gut microbiota-when microbiology Meets Pharmacology. ENVIRON MICROBIOL. 2020;22(3):808–12. · DOI
  13. Yamanishi Y, Choudhury ME, Yoshida A, Hosokawa Y, Miyaue N, Tada S, Ando R, Murakami S, Miyamoto H, Nagai M. Impact of intestinal bacteria on Levodopa pharmacokinetics in LCIG therapy. MOV DISORD CLIN PRAC. 2022;9(3):362–8. · DOI · Paper page
  14. Leta V, Klingelhoefer L, Longardner K, Campagnolo M, Levent HC, Aureli F, Metta V, Bhidayasiri R, Chung-Faye G, Falup-Pecurariu C, et al. Gastrointestinal barriers to Levodopa transport and absorption in parkinson’s disease. EUR J NEUROL. 2023;30(5):1465–80. · DOI
  15. Wei BR, Zhao YJ, Cheng YF, Huang C, Zhang F. Helicobacter pylori infection and parkinson’s disease: etiology, pathogenesis and Levodopa bioavailability. IMMUN AGEING. 2024;21(1):1. · DOI
  16. Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral Levodopa resistance in parkinson’s disease. NPJ PARKINSONS DIS. 2022;8(1):56. · DOI
  17. Danau A, Dumitrescu L, Lefter A, Tulba D, Popescu BO. Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson’s Disease. Int J Mol Sci. 2021;22(21):11663. · DOI
  18. Sampaio TF, Dos SE, de Lima G, Dos AR, Da SR, Asano A, Asano N, Crovella S, de Souza P. MAO-B and COMT genetic variations associated with Levodopa treatment response in patients with parkinson’s disease. J CLIN PHARMACOL. 2018;58(7):920–6. · DOI
  19. Devos D, Lejeune S, Cormier-Dequaire F, Tahiri K, Charbonnier-Beaupel F, Rouaix N, Duhamel A, Sablonniere B, Bonnet AM, Bonnet C, et al. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in parkinson’s disease. PARKINSONISM RELAT D. 2014;20(2):170–5. · DOI
  20. Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, et al. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in parkinson’s disease. Brain. 2015;138(Pt 5):1271–83. · DOI
  21. Dos SE, Sampaio TF, Tenorio DSA, Bezerra LF, Da SR, Crovella S, Asano A, Asano N, de Souza P. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic parkinson’s disease. J PHARM PHARMACOL. 2019;71(2):206–12. · DOI

Metadata

Authors
Feng, Y., Zhang, R., Wen, G., Xie, L., Chen, T., & Liu, W.
Venue
BMC Neurology
Publisher
Springer Science and Business Media LLC
Published
2025-11-10
Volume
25
Issue
1
ISSN
1471-2377
DOI
10.1186/s12883-025-04428-6
Cited by
2
References
5
Language
en
Licence
Funders
  • Youth Project of Hainan Natural Science Foundation (822QN459)
  • National Natural Science Foundation of China (82371268)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of gut microbiota tyrosine decarboxylases in levodopa pharmacokinetics: insights from a levodopa challenge test. https://app.cochat.ai/papers/10.1186/s12883-025-04428-6
The paper
Feng, Y., Zhang, R., Wen, G., Xie, L., Chen, T., & Liu, W. (2025). The role of gut microbiota tyrosine decarboxylases in levodopa pharmacokinetics: insights from a levodopa challenge test. BMC Neurology. https://doi.org/10.1186/s12883-025-04428-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.